Nitric oxide mediates a therapeutic effect of nicotine in ulcerative colitis
Article first published online: 24 DEC 2001
Alimentary Pharmacology & Therapeutics
Volume 14, Issue 11, pages 1429–1434, November 2000
How to Cite
Green, J. T., Richardson, C., Marshall, R. W., Rhodes, J., Mckirdy, H. C., Thomas, G. A. O. and Williams, G. T. (2000), Nitric oxide mediates a therapeutic effect of nicotine in ulcerative colitis. Alimentary Pharmacology & Therapeutics, 14: 1429–1434. doi: 10.1046/j.1365-2036.2000.00847.x
- Issue published online: 24 DEC 2001
- Article first published online: 24 DEC 2001
Ulcerative colitis is a condition of nonsmokers in which nicotine is of therapeutic benefit.
To examine the in vitro effect of nicotine on colonic smooth muscle activity and the role of nitric oxide (NO) as a mediator.
Nicotine, 1–10 μM, was administered to strips of circular muscle from the distal sigmoid colon of 9 patients with active ulcerative colitis and 18 with colorectal cancer. The effect of electrical field stimulation (EFS) was examined before nicotine was added. Finally L-NAME, a NO synthetase inhibitor, was added before nicotine was administered again.
Muscle strips developed similar spontaneous resting tone. In response to EFS, ulcerative colitis tissue developed lower tensions than the controls. Nicotine significantly reduced the resting tone and peak tension after EFS, with a greater effect in controls. With L-NAME, peak tensions were increased more in ulcerative colitis than controls, and nicotine produced a much smaller reduction.
Nicotine reduces circular muscle activity, predominantly through the release of nitric oxide—this appears to be ‘up-regulated’ in active ulcerative colitis. These findings may explain some of the therapeutic benefit from nicotine (and smoking) in ulcerative colitis and may account for the colonic motor dysfunction in active disease.